Overview of 2025

In 2025, medmix operated in a challenging macroeconomic environment marked by softer demand, inflation dynamics, and continued global uncertainty. Despite lower volumes in selected end markets, disciplined execution, careful cost management, and the strength of our global manufacturing and supply‑chain network enabled us to safeguard profitability whilst prioritizing the commercial opportunities in each of our segments.

We continued to advance the strategic transformation and cultural transformation of medmix, sharpening our focus on profitable growth, operational excellence, and customer centricity. Organizational simplification, clearer accountability, and the full deployment of our Growth and Efficiency Program ensured that our cost structure remained aligned with business needs while supporting reinvestment in innovation and market expansion.

Together with the Board of Directors and the Executive Committee, we remain committed to sustainable value creation. This Compensation Report outlines our remuneration framework and the compensation awarded for the 2025 financial year, reflecting our principles of transparency, fairness, and alignment with shareholder interests.